BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
23 July 2024 - 9:00PM
Business Wire
$800 million investment in New Jersey
supports global growth and expansion with technologically advanced
manufacturing capacity and clinical development capabilities for
novel cancer medicines
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology company, today announced the opening of its flagship U.S.
facility in Hopewell, N.J., at the Princeton West Innovation
Campus, which houses state-of-the-art biologics manufacturing
capabilities and a clinical research and development center that
further bolster the Company’s differentiated model as an oncology
innovator. BeiGene has more than 30 molecules at clinical or
commercial stage, and the 42-acre facility provides flexibility to
scale production of its innovative medicines today and in the
future to meet the needs of patients with cancer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240723282527/en/
BeiGene's flagship biologics
manufacturing facility and clinical R&D center at the Princeton
West Innovation Campus in Hopewell, N.J., is seen. (Photo: Business
Wire)
“BeiGene has experienced unprecedented global growth, and the
addition of our facility at the Princeton West Innovation Campus
adds manufacturing and clinical development capabilities that will
further strengthen our differentiated strategy which leverages
speed, efficiency and technology to advance quality medicines
faster for patients,” said John V. Oyler, Co-Founder, Chairman and
CEO of BeiGene. “We are proud to be a part of New Jersey’s
biopharmaceutical community that is rich in research and
development and manufacturing talent. We look forward to deepening
our relationships with key regional research institutions as we
advance our robust pipeline of next-generation hematology and solid
tumor medicines and continue to emerge as a leading global oncology
innovator.”
BeiGene’s $800 million investment is the culmination of a
three-year project to expand the Company’s integrated manufacturing
and research and development footprint in the U.S. BeiGene will
create hundreds of skilled high-tech jobs at the site by the end of
2025. New Jersey is a global leader in biopharmaceutical
manufacturing and R&D with nine of the top 10 R&D companies
in the world having a presence in the state. New Jersey boasts one
of the country’s leading biopharmaceutical manufacturing
workforces, and its infrastructure and connectivity ensure access
to major markets around the world.
“I am thrilled by BeiGene’s contribution to our state’s thriving
biopharmaceutical sector,” said Governor Phil Murphy. “The opening
of BeiGene’s flagship campus underscores our commitment to
fostering innovation and creating high-tech jobs in the Garden
State. We look forward to the positive impact BeiGene will have on
our economy and the advancements they will bring to cancer
treatment. This significant investment highlights New Jersey’s role
as a global leader in pharmaceutical manufacturing, research and
development. We are proud to support BeiGene’s mission to develop
affordable and accessible treatments for cancer patients
worldwide.”
The site features approximately 400,000 square feet of dedicated
commercial-stage biologic pharmaceutical manufacturing capacity
with space to expand over time, allowing flexibility as BeiGene’s
pipeline continues to mature. The facility adds to BeiGene’s
late-stage research and clinical development capabilities, which
have enabled the Company’s fast rise to global oncology leadership.
BeiGene has built one of the industry’s deepest and most compelling
oncology pipelines, addressing 80 percent of the world’s cancers
with innovative modalities such as targeted degraders and antibody
drug conjugates (ADCs), in addition to monoclonal antibodies and
traditional small molecules. The new facility builds on BeiGene’s
existing capabilities, enabling the Company to produce at scale,
thereby reducing costs, ensuring supply chain resiliency, avoiding
global disruptions, protecting capacity and rapidly adapting to the
latest innovative modalities.
“I am excited to welcome BeiGene to Hopewell Township. BeiGene’s
new cutting-edge pharmaceutical facility represents a significant
investment in our community’s future. The life-saving medicines
made right here in Hopewell will not only enhance global cancer
treatment, but will also create good-paying, high-tech jobs and
strengthen our local economy,” said Hopewell Township Mayor
Courtney Peters-Manning. “We look forward to the company’s
continued success in Hopewell Township.”
BeiGene recognizes that human health and the health of the
planet are intrinsically linked, and the Company is committed to
reducing our environmental impact. For this reason, the Company has
invested in sustainability measures both in the buildings and
surrounding 42 acres, including a heating and cooling system that
uses recycled wastewater from the onsite wastewater treatment plant
for the cooling towers. The site also is solar-ready in line with
our longer-term sustainability plan. More details on the facility,
including multimedia assets, are available online at:
https://www.beigene.com/hopewell.
About BeiGene
BeiGene is a global oncology company that is discovering and
developing innovative treatments that are more affordable and
accessible to cancer patients worldwide. With a broad portfolio, we
are expediting development of our diverse pipeline of novel
therapeutics through our internal capabilities and collaborations.
We are committed to radically improving access to medicines for far
more patients who need them. Our growing global team of more than
10,000 colleagues spans five continents. To learn more about
BeiGene, please visit www.beigene.com and follow us on LinkedIn, X
(formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the ability of the Hopewell facility to expand and scale the
Company’s strength around the world; BeiGene’s ability to deepen
relationships with key regional research institutions; and
BeiGene’s plans, commitments, aspirations, and goals under the
heading “About BeiGene.” Actual results may differ materially from
those indicated in the forward-looking statements as a result of
various important factors, including BeiGene’s ability to
demonstrate the efficacy and safety of its drug candidates; the
clinical results for its drug candidates, which may not support
further development or marketing approval; actions of regulatory
agencies, which may affect the initiation, timing, and progress of
clinical trials and marketing approval; BeiGene’s ability to
achieve commercial success for its marketed medicines and drug
candidates, if approved; BeiGene’s ability to obtain and maintain
protection of intellectual property for its medicines and
technology; BeiGene’s reliance on third parties to conduct drug
development, manufacturing, commercialization, and other services;
BeiGene’s limited experience in obtaining regulatory approvals and
commercializing pharmaceutical products; BeiGene’s ability to
obtain additional funding for operations and to complete the
development of its drug candidates and achieve and maintain
profitability; and those risks more fully discussed in the section
entitled “Risk Factors” in BeiGene’s most recent quarterly report
on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in BeiGene’s subsequent
filings with the U.S. Securities and Exchange Commission. All
information in this press release is as of the date of this press
release, and BeiGene undertakes no duty to update such information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723282527/en/
Investors: Liza Heapes +1 857-302-5663 ir@beigene.com
Media: Kyle Blankenship +1 667-351-5176
media@beigene.com
To access BeiGene media resources, please visit our News
& Media site.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024